Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity

Obesity

Volumn 19, Issue 3, 2011, Pages 505-513

  Wang, Qun ^a,b   Perrard, Xiaoyuan D ^a   Perrard, Jerry L ^a   Mansoori, Amir ^a   Smith, C Wayne ^a   Ballantyne, Christie M ^a,c   Wu, Huaizhu ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; CHOLESTEROL; FATTY ACID; GLUCOSE; INSULIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RIMONABANT; TRIACYLGLYCEROL;

ACETYL COA CARBOXYLASE GENE; ADIPONECTIN GENE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY FAT; CD11B GENE; CD11C GENE; CD3 GENE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; ELOVL 6 GENE; EOTAXIN GENE; EXPLANT; F4 80 GENE; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHASE GENE; FATTY LIVER; GENE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIPID LIVER LEVEL; LIVER WEIGHT; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA GENE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA GENE; MACROPHAGE INFLAMMATORY PROTEIN 2 GENE; MALE; MONOCYTE CHEMOTACTIC PROTEIN 1 GENE; MOUSE; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; RANTES GENE; SREBP1C GENE; STEAROYL COA DESATURASE 1 GENE; T CELL ANTIGEN RECEPTOR ALPHA GENE; T CELL RECEPTOR ALPHA GENE; T LYMPHOCYTE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANIMALS; ANTI-OBESITY AGENTS; CHEMOKINE CCL2; DIET; DIETARY FATS; DISEASE MODELS, ANIMAL; ENERGY INTAKE; INFLAMMATION; LIVER; MICE; MICE, INBRED C57BL; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; WEIGHT GAIN; WEIGHT LOSS;

MUS;

EID: 79952008057     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2010.213     Document Type: Article

References (44)

1. Wu H, Ghosh S, Perrard XD et al. T-cell accumulation and regulated on activation, normal T-cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007;115:1029-1038. (Pubitemid 46328297)
2. Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808. (Pubitemid 38063703)
3. Wu H, Perrard X-YD, Wang Q, et al. CD11c expression in adipose tissue and blood and its role in diet-induced obesity. Arterioscler Thromb Vasc Biol 2010;30:186-192.
4. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-953.
5. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867. (Pubitemid 46024993)
6. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-880. (Pubitemid 46028447)
7. Ziccardi P, Nappo F, Giugliano G et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002;105:804-809. (Pubitemid 34174919)
8. Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815-3819. (Pubitemid 32755982)
9. Jesudason D, Wittert G. Endocannabinoid system in food intake and metabolic regulation. Curr Opin Lipidol 2008;19:344-348.
10. Després JP, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134. (Pubitemid 41653104)
11. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-775. (Pubitemid 43244304)
12. Bensaid M, Gary-Bobo M, Esclangon A et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-914. (Pubitemid 36368998)
13. Jbilo O, Ravinet-Trillou C, Arnone M et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005;19:1567-1569. (Pubitemid 41279033)
14. Getty-Kaushik L, Richard AM, Deeney JT et al. The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets. Obesity (Silver Spring) 2009;17:1856-1860.
15. Schäfer A, Pfrang J, Neumüller J et al. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces proinflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol 2008;154:1047-1054. (Pubitemid 351915060)
16. Wu H, Rodgers JR, Perrard XY et al. Deficiency of CD11b or CD11d results in reduced staphylococcal enterotoxin-induced T-cell response and T-cell phenotypic changes. J Immunol 2004;173:297-306. (Pubitemid 38797354)
17. Poirier B, Bidouard JP, Cadrouvele C et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005;7:65-72.
18. Nadler ST, Stoehr JP, Schueler KL et al. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci USA 2000;97:11371-11376.
19. Cota D, Sandoval DA, Olivieri M et al. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring) 2009;17:1641-1645.
20. Verty AN, Allen AM, Oldfield BJ. The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity (Silver Spring) 2009;17:254-261.
21. Starowicz KM, Cristino L, Matias I et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008;16:553-565. (Pubitemid 351328005)
22. Matias I, Gonthier MP, Orlando P et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91:3171-3180. (Pubitemid 44271774)
23. Côté M, Matias I, Lemieux I et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007;31:692-699. (Pubitemid 46482358)
24. Després JP, Ross R, Boka G, Alméras N, Lemieux I. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intra-abdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009;29:416-423.
25. Herling AW, Kilp S, Juretschke HP et al. Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant. Int J Obes (Lond) 2008;32:1363-1372.
26. Jourdan T, Djaouti L, Demizieux L et al. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010;59:926-934.
27. Di Marzo V, Després JP. CB1 antagonists for obesity - what lessons have we learned from rimonabant? Nat Rev Endocrinol 2009;5:633-638.
28. Pagano C, Pilon C, Calcagno A et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007;92:4810-4819. (Pubitemid 350223464)
29. Bellocchio L, Cervino C, Vicennati V, Pasquali R, Pagotto U. Cannabinoid type 1 receptor: another arrow in the adipocytes' bow. J Neuroendocrinol 2008;20(Suppl)1:130-138. (Pubitemid 351559286)
30. Weisberg SP, Hunter D, Huber R et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006;116:115-124. (Pubitemid 43121796)
31. Gunn MD, Nelken NA, Liao X, Williams LT. Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activation. J Immunol 1997;158:376-383. (Pubitemid 127483879)
32. Patsouris D, Li PP, Thapar D et al. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 2008;8:301-309.
33. Osei-Hyiaman D, Liu J, Zhou L et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008;118:3160-3169.
34. Gary-Bobo M, Elachouri G, Gallas JF et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007;46:122-129. (Pubitemid 47171928)
35. Tam JVV, Liu J, Bátkai S, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010;120:2953-2966.
36. Koolman AH, Bloks VW, Oosterveer MH et al. Metabolic responses to longterm pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition. Int J Obes (Lond) 2010;34:374-384.
37. D'Eon TM, Pierce KA, Roix JJ et al. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008;57:1262-1268.
38. Di Marzo V, Verrijken A, Hakkarainen A et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009;161:715-722.
39. Hoogeveen RC, Morrison A, Boerwinkle E et al. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005;183:301-307. (Pubitemid 41579281)
40. Kim CS, Park HS, Kawada T et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 2006;30:1347-1355. (Pubitemid 44306516)
41. Hegde VL, Hegde S, Cravatt BF et al. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T-cells. Mol Pharmacol 2008;74:20-33. (Pubitemid 351872155)
42. Ashton JC. Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs 2007;8:373-384. (Pubitemid 46705390)
43. Maresz K, Pryce G, Ponomarev ED et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T-cells. Nat Med 2007;13:492-497. (Pubitemid 46559830)
44. Croci T, Zarini E. Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. Br J Pharmacol 2007;150:559-566. (Pubitemid 46355562)